Language

CAS No. 2050057-56-0 | Upadacitinib hemihydrate

CAS No. 2050057-56-0 | Upadacitinib hemihydrate

Name: Upadacitinib hemihydrate CAS No. 2050057-56-0 MF:C17H21F3N6O2 MW:398.39 Purity:99% Package: 10g,25g,50g,100g,250g Worldwide Delivery

Categories：

Biochemicals

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

Introduction and application of CAS No. 2050057-56-0 | Upadacitinib hemihydrate

Synonyms:1-Pyrrolidinecarboxamide,3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-,hydrate(2:1),(3S,4R)-;

Upadacitinibhemihydrate;

UpadacitinibHydrate;

Cinchonanium,1-[13,5-bis(trifluoromethyllphenyllmethyl]-9-hydroxy-1'-[[3-(trifluoromethyl)phenyllmethyl},bromide(1:2),(8a,9R)-"

Specification:

ITEMS	SPECIFICATION
CAS	2050057-56-0
MF	C17H21F3N6O2
MW	398.39

application:

Upatinib is an oral Janus kinase (JAK) 1 selective inhibitor and a disease-modifying antirheumatic drug. Upatinib is used to treat rheumatoid arthritis to slow disease progression, rheumatoid arthritis. It is a chronic autoimmune inflammatory disease affecting peripheral joints and is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage, and bone destruction, leading to comorbidities.

Biological activity:

The chemical nature of Upatinib hemihydrate is Upatinib, which is an oral Janus kinase isoform 1 (JAK1) selective inhibitor. JAK belongs to the cytoplasmic tyrosine kinase family, and its function is to transmit signals mediated by cytokines (such as interferons). There are four JAK subtypes, and there are overlapping binding partners between the subtypes.

Package and transportation :

Package: 10g,25g,50g,100g,250g